Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at .
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, .
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
Media Contact:
EvolveMKD
646-517-4220
